Cancer's SOS

Credit: CC0 Public Domain

RAS proteins regulate growth, survival and proliferation of cells in their active state. However, the uncontrolled activation of RAS causes approximately a third of all tumors and helps cancerous cells evade anti-cancer drugs. Thus RAS is an important target for effective anti-cancer treatments.

RAS proteins become "active" through the exchange of guanine nucleotides (GTP for GDP), which is catalyzed by guanine nucleotide exchange factor proteins such as Son of Sevenless homologue 1 (SOS1).

Stephen Fesik, Ph.D., and colleagues previously discovered that bind to SOS1 and activate nucleotide exchange on RAS.

Now, in the journal ACS Chemical Biology, they report that these compounds modulate two downstream signaling pathways via independent cellular responses. They also identify a potent SOS1 agonist that rapidly elicits on-target molecular effects at substantially lower concentrations than those causing off-target effects.

The discovery, they concluded, will allow them to further define the on-target utility of SOS1 agonists and to advance their drug-discovery efforts.

Explore further

New idea for targeting the common cancer protein KRAS

More information: Denis T. Akan et al. Small Molecule SOS1 Agonists Modulate MAPK and PI3K Signaling via Independent Cellular Responses, ACS Chemical Biology (2019). DOI: 10.1021/acschembio.8b00869
Journal information: ACS Chemical Biology

Citation: Cancer's SOS (2019, April 5) retrieved 16 September 2019 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more